1. Market Research
  2. > Pharmaceutical Market Trends
Merck & Co

Merck & Co

  • April 2020
  • 72 pages
  • ID: 5779830
  • Format: PDF
  • Pharma Intelligence

Summary

Table of Contents

PharmaVitae explores Merck and Co’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Merck and Co’s revenue growth will be fairly stable over the forecast period, as growth from Keytruda and Gardasil will be offset by declines from Januvia, Janumet, and the spin-off of Women’s Health and Legacy Brands.
Key themes – [1] Keytruda will see strong growth over the forecast period until loss of exclusivity in 2028, although 2020 growth will be negatively impacted by two large price reductions in Japan [2] Merck’s metabolic portfolio will decline significantly due to patent expiries for key drugs Januvia and Janumet [3] Merck’s late-stage pipeline is heavily skewed towards label expansions for its existing oncology portfolio, with only a few new drug launches expected over the forecast period.

Model updates (4 March 2020)

Keytruda forecast adjusted lower due to 2020 impact of two significant price reductions in Japan
Gardasil forecast adjusted higher due to strong demand globally
Lenvima Alliance Revenue forecast added
Lynparza Alliance Revenue forecast added
Zetia forecast removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Vytorin removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
NuvaRing removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Implanon removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Singulair removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Cozaar removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Nasonex removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Arcoxia removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands
Follistim removed after mid-2021 due to Merck spin-off of Women’s Health and Legacy Brands.

Model updates (4 November 2019)

Keytruda forecast adjusted higher due to continued momentum in all of NSCLC, including first-line monotherapy in China, as well as continued uptake in other cancer indications, including recently launched renal cell carcinoma and adjuvant melanoma indications
Gardasil forecast adjusted lower in the near term due to supply constraints, which will alleviate in 2023 upon completion of additional production capabilities.

Model updates (7 August 2019)

Keytruda forecast adjusted higher due to continued share gains in first-line NSCLC and other label expansions
Gardasil forecast adjusted higher due to increasing vaccination rates globally, positive pricing, and the ongoing commercial launch in China
ProQuad / M-M-R II / Varivax forecast adjusted higher due to higher vaccination rates and favorable pricing
Remicade forecast adjusted lower due to continued biosimilar competition and pricing pressure in Europe
Simponi forecast adjusted lower due to biosimilar competition in the immunology and inflammation space impacting growth
Gefapixant forecast added
Vericiguat forecast added.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on